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Abstract  Demyelinating  conditions  of  the  central  nervous  system  can  be  associated  with
inﬂammatory  bowel  disease,  but  since  the  introduction  of  tumour  necrosis  factor  antagonist
therapies,  a  number  of  cases  of  demyelinating  disease  associated  with  the  treatment  are  being
described.
We report  the  case  of  a  36-year-old  female,  with  Crohn’s  disease,  treated  with  adalimumab
for eighteen  months.  She  developed  severe  headache  and  the  investigations  disclosed  several
demyelinating  lesions  in  the  sub  cortical  white-matter  of  the  frontal  and  parietal  lobes.  The
suspension  of  adalimumab  resulted  in  symptomatic  relief  in  a  few  weeks,  but  the  brain  lesions
persisted after  eight  months  of  follow-up.
The  cause  of  these  lesions  in  inﬂammatory  bowel  disease  patients  treated  with  tumour  necro-
sis factor  antagonists  is  not  yet  clearly  established,  but  a  raised  awareness  to  this  possibility  is
important, as  an  early  change  of  treatment  is  recommended.
© 2011  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
PALAVRAS-CHAVE
Desmielinizac¸ão;
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Adalimumab
Lesões  cerebrais  desmielinizantes  em  doente  com  doenc¸a de  Crohn  sob  adalimumab
Resumo  As  lesões  desmielinizantes  podem  ocorrer  na  doenc¸a  inﬂamatória  intestinal,  mas,
desde a  introduc¸ão  das  terapêuticas  com  antagonistas  do  factor  de  necrose  tumoral,  os  casos
de lesões  desmielizantes  associados  ao  tratamento  têm  vindo  a  ser  cada  vez  mais  descritos.
Descrevemos  o  caso  de  uma  mulher  de  36  anos,  com  doenc¸a  de  Crohn,  tratada  com  adal-
imumab durante  dezoito  meses.  Desenvolveu  cefaleias  intensas  cuja  investigac¸ão  levou  ao
achado de  lesões  desmielinizantes  na  substância  branca  frontal  e  parietal.  A  suspensão  do  adal-
imumab levou  a  rápida  melhoria  sintomática,  mas  as  imagens  das  lesões  encefálicas  persistiram
inalteradas  oito  meses  depois.
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A  causa  destas  lesões  não  está  deﬁnitivamente  estabelecida  e  o  seu  mecanismo  é  complexo;  é
importante  considerar  precocemente  esta  possibilidade  em  doentes  tratados  com  antagonistas
do factor  de  necrose  tumoral,  pois  recomenda-se  uma  mudanc¸a  da  estratégia  terapêutica  nestas
situac¸ões.
© 2011  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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nﬂammatory  bowel  disease  (IBD)  is  often  associated  with
 variety  of  extra-intestinal  manifestations;  among  these,
eurological  and  neuromuscular  manifestations  are  well
nown.1,2 They  can  result  from  the  disease  itself,  by  nutri-
nt  malabsortion,  by  thromboembolic  events  or  by  changes
n  immunologic  processes.  They  can  also  be  related  to
reatment,  either  as  a  side  effect  of  medication  or  as  an
nfectious  consequence  of  immunosuppression.
Peripheral  neuropathy  and  cranial  nerve  lesions  can  occur
n  IBD,3--6 and  nerve  demyelination  is  considered  to  result
rom  ischemia  related  to  hypercoagulation  or  vasculitis.  On
he  other  hand,  the  central  nervous  system  (CNS)  can  be
nvolved  in  up  to  4%  of  IBD  patients,7 often  with  cerebrovas-
ular  disease  also  caused  by  vasculitis,  by  thrombosis  or
y  haemorrhage  related  to  coagulopathy.  Clinical  patterns
f  multiple  sclerosis  are  also  associated  to  IBD,8--10 either
efore  or  after  its  diagnosis.  The  number  of  those  cases  is
mall,  so  it  is  not  clear  if  a  causal  relationship  exists,  or  if
here  is  an  increased  susceptibility  to  multiple  sclerosis  in
BD  patients.11 Moreover,  the  differential  diagnosis  between
ultiple  sclerosis  and  CNS  vasculitis  in  an  IBD  patient  can
e  difﬁcult,  thus  reducing  the  number  of  reported  patients
ith  a  correct  diagnosis.
We  report  the  case  of  a  Crohn’s  disease  patient  with
emyelinating  brain  lesions  associated  with  the  use  of
umour  necrosis  factor   antagonists  (anti-TNF).
ase report
 35-year-old  Caucasian  female  was  referred  to  the
astroenterology  outpatient  clinic  because  of  diarrhoea.
rohn’s  disease  was  diagnosed  at  another  hospital  six  years
efore,  after  an  ileocolonic  resection  for  acute  ileitis.  She
as  on  oral  mesalazine,  and  she  complained  of  frequent
iarrhoea  without  blood,  sometimes  with  abdominal  pain,
elieved  by  oral  prednisolone  for  short  periods  of  time.
hese  symptoms  were  well  tolerated,  her  weight  was  sta-
le  and  she  denied  fever  or  loss  of  appetite.  She  was  a
on-smoker,  she  denied  any  neurological  symptoms  and  no
elevant  diseases  were  found  in  her  past  and  familial  his-
ory.  Physical  exam  showed  a  patient  in  a  good  nutritional
tatus,  with  normal  body  temperature  and  blood  pressure.
kin  and  oral  mucosa  were  normal,  and  so  was  the  cardiopul-
onary  examination.  The  abdominal  examination  disclosed median  laparotomy  scar  and  a  painless  ovoid  10  cm  mass
ould  be  felt  by  palpation  in  the  deep  right  lower  quadrant.
he  initial  blood  tests  were  within  normal  range,  including
he  ESR  and  the  C-reactive  protein.  Oral  budesonide  3  mg  tid
D
O
tas  started,  followed  later  by  oral  azathioprine  100  mg/day,
ater  increased  to  150  mg/day.
The  symptoms  markedly  improved  and  ﬁve  months  later
 MRI  enterography  did  not  ﬁnd  signs  of  active  inﬂammation.
wo  bouts  of  diarrhoea  and  abdominal  pain  needing  oral  cor-
icosteroids  occurred  in  the  following  months  and  a  decision
o  start  anti-TNF  treatment  was  made.  As  no  contraindica-
ions  were  present,  subcutaneous  adalimumab  was  started
nd,  after  the  induction,  the  patient  remained  on  40  mg  of
dalimumab  every  other  week.  Eighteen  months  after  the
tart  of  the  anti-TNF  treatment,  the  patient  was  free  of  cor-
icosteroid  use,  azathioprine  had  been  stopped,  inﬂuenza
mmunization  had  been  given  and  only  two  short  bouts  of
iarrhoea  had  occurred,  easily  managed  with  symptomatic
edication.  Laboratory  evaluation  showed  slight  normo-
ytic  normochromic  anaemia,  with  a  haemoglobin  value  of
0.9  g/dL,  with  all  the  other  laboratory  ﬁndings  within  nor-
al  limits.
After  eighteen  months  of  adalimumab  treatment  the
atient  complained  of  diffuse  headache,  gradually  more
ntense,  without  photophobia,  visual  impairment,  fever,
izziness,  nausea  or  vomiting.  There  was  no  muscle  or
oint  pain,  and  no  skin  lesions  were  present.  The  neuro-
ogical  evaluation  was  normal,  without  signs  of  meningitis
r  peripheral  neuropathy.  Blood  white  and  red  cell  counts
ere  normal,  ESR  was  46  mm  at  1  h,  C-reactive  protein
as  0.9  mg/mL.  Antinuclear  antibody  was  positive  up  to  a
ilution  of  1/360,  but  other  autoantibodies  and  serologic
arkers  suggesting  vasculitis  were  absent.
Brain  CT  showed  small  hypodense  lesions  in  the  frontal
hite-matter  subcortical  layer,  suggesting  demyelinating
esions.  MRI  revealed  several  demyelinating  lesions  in  the
hite-matter  of  both  hemispheres,  showing  as  hyper-
ignal  in  protonic  and  T2  density,  with  different  sizes  and
ounded  shapes  (Fig.  1).  Their  topography  was  subcortical,
oth  frontal  and  parietal.  These  lesions  were  suggestive
f  demyelinating  lesions  related  to  chronic  small-vessel
schemia.  The  eco-Doppler  study  of  the  large  neck  arteries
ailed  to  show  any  abnormalities  and  the  patient  declined  a
pinal  tap.
Adalimumab  was  stopped  and  a  progressive  symptomatic
elief  was  evident  along  the  next  two  months.  Immunossu-
ression  with  azathioprine  was  restarted  at  150  mg/day  and
o  IBD  ﬂares  were  noted  during  the  eight  months  of  follow-
p.  Despite  the  clinical  improvement  a  second  MRI  conﬁrmed
he  persistence  of  the  white-matter  lesions.iscussion
ur  patient  had  an  ileal  Crohn’s  disease  with  inﬂamma-
ory  phenotype,  already  submitted  to  surgical  resection  and
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mFigure  1  Brain  MRI  showing  small  rounded  lesions  (ar
needing  frequent  systemic  corticosteroids.  The  indication
for  anti-TNF  therapy  was  clear,  and  as  absence  from  work
could  be  a  problem,  adalimumab  was  the  patient’s  option
with  satisfactory  clinical  and  radiologic  evolution  of  the
intestinal  disease.
Neurologic  symptoms  started  eighteen  months  after
treatment.  The  CNS  lesions  suggested  a  demyelinating
condition  similar  to  multiple  sclerosis,  but  the  possibility
of  an  IBD-associated  vasculitis  was  also  considered,  espe-
cially  taking  in  account  the  MRI  images.  However,  clinical
ﬁndings  of  primary  vasculitis  were  absent,  namely  fever,
muscle  pain,  arthritis,  skin  lesions,  peripheral  neuropathy
or  signs  of  renal  lesion.  Chest  radiograph,  serum  creati-
nine,  liver  and  muscle  enzymes  and  urinary  sediment  were
normal.  Viral  serologies  were  negative,  and  autoantibodies
titers  were  low,  excepting  the  antinuclear  antibody  titer
that  was  positive  at  1/360  dilution  --  but  an  isolated  high
antinuclear  antibody  titer  is  frequent  in  patients  on  anti-
TNF  therapy,12 and  can  even  occur  in  normal  persons.  In
addition,  primary  CNS  vasculitis  is  rare,  and  systemic  vas-
culitis  with  brain  involvement  would  be  expected  to  cause
larger  lesions.13
The  use  of  anti-TNF  in  the  treatment  of  IBD  represented
a  major  therapeutic  advance,  allowing  signiﬁcant  beneﬁts
in  the  induction  and  maintenance  of  remission  in  Crohn’s
disease.  However,  in  spite  of  an  adequate  evaluation  and
selection  of  patients,  important  complications  can  occur,
some  of  them  involving  the  CNS.  Anti-TNF  associated  CNS
lesions  have  been  reported  in  IBD,  related  both  to  the  use
of  inﬂiximab  or  adalimumab14;  it  is  a  matter  of  debate  if
those  lesions  are  a  direct  consequence  of  the  treatment,  or
if  the  treatment  just  uncovers  a  subclinical  demyelinating
condition.
The  demyelinating  lesions  associated  to  the  anti-TNF
therapy  are  infrequent  but  their  early  detection  is  impor-
tant,  so  all  neurological  symptoms  in  these  patients  must
be  carefully  evaluated  at  any  point  during  the  course  of
the  treatment.  The  postulated  mechanism  for  the  lesions
involves  the  activation  of  myelin-speciﬁc  T  cells;  these
cells  would  migrate  into  the  CNS  thus  causing  the  lesions.
The  more  frequent  complaints  are  related  to  paresthe-
sia,  headache,  confusion  and  visual  or  gait  impairment.15Severe  forms  of  Guillain-Barré  syndrome  are  also  reported.
These  manifestations  can  occur  when  the  treatment  starts
or  many  months  after  the  beginning  of  the  therapy.  A  CNS
MRI  will  show  a  pattern  of  white-mater  lesions  similar  of
s
o
n)  in  the  subcortical  white-matter  of  both  hemispheres.
hose  found  in  multiple  sclerosis.16 The  precise  evaluation  of
hese  ﬁnding  may  be  difﬁcult  taking  in  account  the  reported
ccurrence  of  similar  ﬁndings  in  IBD  patients  not  treated
ith  anti-TNF  and  even  in  normal  controls17 -- although  other
tudies  have  found  those  lesions  to  be  much  less  frequent.18
he  use  of  MRI  angiography  of  the  CNS  or  the  study  of  the
erebrospinal  ﬂuid  may  be  helpful  in  selected  cases.
The  clinical  trials  with  adalimumab  reported  demyelinat-
ng  disease  in  0.2%  of  the  3160  patients  treated  up  to  2009,19
ut  in  spite  of  this  low  incidence  we  have  considered  an  asso-
iation  between  adalimumab  treatment  and  demyelinating
esion  in  our  patient.
The  headache  complaints  began  six  weeks  after  the  anti-
nﬂuenza  vaccination,  and  a hypothetic  relation  between
he  two  events  was  considered.  Despite  a  few  reported  cases
ssociating  the  two  events,  anti-inﬂuenza  vaccination  is  not
onsidered  a  cause  of  demyelination,  and  does  not  cause
ymptoms  in  patients  with  subclinical  disease.20 Moreover,
he  National  Multiple  Sclerosis  Society  considers  that  the
easonal  inﬂuenza  vaccination  for  2010--2011,  which  covers
1N1  strain,  is  safe  and  should  be  administered  to  multi-
le  sclerosis  patients  even  when  those  patients  are  under
reatment  with  interferon  or  natalizumab.21
As  soon  as  the  white-matter  demyelinating  lesions  are
ound,  cessation  of  anti-TNF  treatment  is  recommended  as
his  leads  to  an  improvement  in  most  patients.1 However  the
ourse  of  the  neurological  manifestations  is  unpredictable  in
ach  individual  case.22 In  agreement  with  published  reports
nd  recommendations,19 anti-TNF  therapy  was  suspended.
he  option  for  azathioprine  was  based  on  the  need  to  main-
ain  an  adequate  immunosuppression.  The  possibility  of
witching  to  inﬂiximab  was  discussed,  but  the  anti-TNF  asso-
iated  demyelinating  lesions  are  considered  a  class  effect
G.  Van  Assche,  personal  communication)  and  this  option
as  no  support  from  the  published  literature.
There  was  a  temporal  relation  between  the  symptomatic
mprovement  of  our  patient  and  the  adalimumab  cessation,
nd  the  patient  regained  a  stable  clinical  condition  that
llowed  her  to  keep  her  usual  daily  activities.  Neurological
igns  or  symptoms  are  not  expected  in  the  future,  but  so  far
e  cannot  deﬁnitely  exclude  the  possibility  of  a  subclinical
ultiple  sclerosis  unmasked  by  the  exposure  to  anti-TNF,o  the  patient  is  still  under  surveillance  at  the  neurology
utpatient  clinic.
This  case  report  reminds  us  of  the  possible  occurrence  of
eurological  lesions  in  IBD  patients,  especially  in  those  on
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22  
nti-TNF  treatment.  An  early  detection  and  the  immediate
reatment  change  can  prevent  irreversible  lesions  or  severe
eurological  impairment.
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